Gluconova: A Phytoengineered Passiflora Edulis-Based Polyherbal System for Precision Glycemic Homeostasis

1.Gourkar Khushi Sanjay 2. Dr. Tambe Sagar Eknath 3. Jogdand Akanksha Vinod 4. Shirole Saloni

1.Student Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra.

2.Assistant Professor, Department of Pharmaceutical Chemistry, Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra.

3. Student Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra.

4. Student Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra.

How to Cite this Article:
Sanjay, G. K., Vinod, J. A. & Saloni, S. (2026). Gluconova: A Phytoengineered Passiflora Edulis-Based Polyherbal System for Precision Glycemic Homeostasis. International Journal of Creative and Open Research in Engineering and Management, 02(05). https://doi.org/10.55041/ijcope.v2i5.775



https://doi.org/10.55041/ijcope.v2i5.775

Abstract

GLUCONOVA is an innovative polyherbal tablet formulation combining three ethnopharmacologically validated plant sources — Passiflora edulis (passion fruit leaves), Coccinia grandis (ivy gourd), and Nigella sativa (kalonji/black seed) — designed for the management of Type 2 Diabetes Mellitus (T2DM). This review aims to explore the therapeutic potential of GLUCONOVA, highlighting the phytochemical composition, individual and combined antidiabetic mechanisms, formulation rationale, preclinical and clinical evidence, safety profile, and future prospects of this polyherbal system.

Each constituent plant contributes a distinct pharmacological mechanism: Passiflora edulis leaves provide orientin, vitexin, and chrysin that exhibit insulin mimetic and beta-cell protective activity; Coccinia grandis supplies cucurbitacins and flavonoids that inhibit hepatic glucose output and enhance peripheral glucose utilization; and Nigella sativa contributes thymoquinone, which is renowned for its insulin-sensitizing, antioxidant, and anti-inflammatory properties. Together, these phytochemicals form a synergistic matrix targeting multiple nodes of glucose dysregulation, making GLUCONOVA a promising candidate for precision glycemic homeostasis.

Keywords: *Passiflora edulis; Coccinia grandis; Nigella sativa; polyherbal formulation; Type 2 Diabetes Mellitus; glycemic control; thymoquinone; orientin; phytomedicine*

1. INTRODUCTION

Diabetes mellitus is among the most pressing non-communicable disease challenges of the twenty-first century, with the International Diabetes Federation reporting over 537 million adults living with the condition worldwide. Type 2 Diabetes Mellitus (T2DM), accounting for approximately 90–95% of all diabetic cases, is characterized by progressive insulin resistance, deteriorating pancreatic beta-cell function, dyslipidemia, and chronic systemic inflammation. Despite remarkable advances in synthetic pharmacotherapy — including metformin, sulfonylureas, GLP-1 receptor agonists, and SGLT-2 inhibitors — complete glycemic normalization remains elusive for many patients, and long-term pharmacological therapy is often accompanied by adverse effects and significant economic burden.

Against this backdrop, traditional systems of medicine including Ayurveda, Unani, and indigenous healing practices have preserved a rich legacy of plant-based antidiabetic interventions. A critical limitation of many existing herbal preparations is their reliance on single-herb formulations, which offer narrow mechanistic coverage. Modern understanding of T2DM as a multifactorial syndrome demands pharmacological interventions that simultaneously address multiple etiological targets.(10)

This comprehensive review aims to examine the therapeutic potential of GLUCONOVA — a phytoengineered polyherbal tablet system — integrating contemporary scientific insights with traditional ethnobotanical knowledge. The formulation's name captures its dual identity: 'Gluco' reflecting its primary glycemic orientation, and 'Nova' signifying novelty and innovation in phytotherapeutic science.

2. History of GLUCONOVA Constituent Herbs

The three botanical components of GLUCONOVA each carry a distinguished history in traditional medicine systems spanning multiple centuries and civilizations.

2.1 Passiflora edulis (Passion Fruit Leaf)

Passiflora edulis, belonging to the family Passifloraceae, is indigenous to South America and is widely cultivated across tropical Asia and Africa. Traditional healers in Brazil have documented the use of passion fruit leaf infusions for the management of diabetes (locally termed 'doença do açúcar'), as well as for anxiety and hypertension. In the Ayurvedic tradition, Passiflora is recognized for restoring balance to the body's metabolic function, and indigenous communities in India traditionally prepare leaf decoctions to combat polyuria and fatigue — hallmark symptoms of uncontrolled hyperglycemia.

Fig. Passion Fruit Leaves

2.2 Coccinia grandis (Ivy Gourd)

Coccinia grandis, commonly known as ivy gourd or 'kundru,' is a perennial climber from the family Cucurbitaceae. It is described in Ayurveda under the Sanskrit designation 'Bimbi' and classified as a 'Pramehaghna' herb — one specifically indicated for prameha, the ancient Indian conceptualization of urinary and diabetic disorders. Ethnobotanical surveys in Bangladesh, Thailand, and India consistently document the use of its leaves for the management of hyperglycemia through traditional decoctions and leaf juice preparations.

2.3 Nigella sativa (Kalonji / Black Seed)

Nigella sativa, belonging to the family Ranunculaceae, holds extraordinary cultural and medicinal significance across Islamic, Ayurvedic, and Greco-Arabic traditions. In Unani medicine, it is classified as a carminative, diuretic, and antidiabetic agent. Ethnopharmacological surveys across the Middle East, South Asia, and North Africa document its consistent use for blood sugar regulation, often alongside conventional antidiabetics, with subjectively reported improvements in fasting glucose and urinary frequency.

Fig. Kalonji

Table 1: Taxonomical Classification of GLUCONOVA Constituent Herbs

Category	Passiflora edulis	Coccinia grandis	Nigella sativa
Kingdom	Plantae	Plantae	Plantae
Division	Tracheobionta	Tracheobionta	Tracheobionta
Class	Magnoliopsida	Magnoliopsida	Magnoliopsida
Order	Malpighiales	Cucurbitales	Ranunculales
Family	Passifloraceae	Cucurbitaceae	Ranunculaceae
Genus	Passiflora	Coccinia	Nigella
Common Name	Passion Fruit	Ivy Gourd / Kundru	Kalonji / Black Seed

3. Chemical Background of GLUCONOVA Constituents

The three herbal components of GLUCONOVA collectively provide a rich profile of bioactive compounds, including flavonoids, alkaloids, terpenoids, quinones, phenolics, and saponins, which contribute to their antidiabetic properties.

3.1 Key Chemical Compounds in Passiflora edulis Leaves

- C-Glycosylflavones: Orientin (8-C-glucosylapigenin) and vitexin are the dominant flavonoids, demonstrating alpha-glucosidase inhibitory activity and AMPK activation.
- Chrysin (5,7-dihydroxyflavone): Exhibits anti-inflammatory activity through NF-kB pathway suppression and beta-cell protective effects.
- Alkaloids: Passiflorine and harman, contributing mild CNS modulating effects relevant to stress-induced hyperglycemia.
- Flavonols: Quercetin, rutin, kaempferol, and isoorientin providing antioxidant support.

3.2 Key Chemical Compounds in Coccinia grandis

• Cucurbitacins: Cucurbitacin B and E, triterpene compounds demonstrating insulin-mimetic activity by enhancing GLUT-4 expression.

• Flavonoids: Apigenin, myricetin, luteolin, and quercetin glycosides contributing antioxidant and alpha-glucosidase inhibitory activity.

• Steroidal Saponins: Implicated in enhanced insulin receptor sensitivity by modulating membrane fluidity.

• Carotenoids: Lycopene and beta-carotene providing antioxidant protection to pancreatic beta cells.

3.3 Key Chemical Compounds in Nigella sativa

• Thymoquinone (TQ): The principal bioactive, constituting 28–57% of the volatile oil. Multidimensional antidiabetic activity including insulin secretion stimulation and insulin sensitization.

• Thymohydroquinone and Thymol: Additional quinone compounds modulating lipid metabolism and oxidative stress.

• Alpha-hederin and Nigellicine: Alkaloid constituents with anti-inflammatory and hepatoprotective properties.

• Fixed Oils: Linoleic and oleic acid contributing to improved lipid profiles and enhanced cell membrane fluidity.

Table 2: Comparative Phytochemical Profile of GLUCONOVA Constituents

Herb	Major Bioactives	Phytochemical Class	Primary Role
Passiflora edulis	Orientin, Vitexin, Chrysin, Quercetin, Passiflorine	C-glycosylflavones, Alkaloids, Flavonols	Enzyme inhibition, AMPK activation, GLUT-4 upregulation
Coccinia grandis	Cucurbitacin B & E, Luteolin, Myricetin, Beta-carotene	Triterpenes, Flavonoids, Carotenoids, Saponins	Insulin mimesis, PTP-1B inhibition, Beta-cell protection
Nigella sativa	Thymoquinone, Thymohydroquinone, Alpha-hederin, Nigellicine	Quinones, Alkaloids, Fixed oils, Terpenes	Insulin secretion, Gluconeogenesis suppression, NF-kB inhibition

4. Key Findings from Review Articles

Pharmacological Properties:

Studies confirm the traditional uses of all three GLUCONOVA herbs for diabetes management, with scientific evidence supporting their role in reducing blood glucose, improving insulin sensitivity, reducing inflammation, and fighting oxidative stress.

Phytochemical Composition:

The antidiabetic properties of these herbs are linked to their diverse bioactive compounds — particularly orientin, cucurbitacins, and thymoquinone — which interact with multiple molecular targets in glucose metabolism pathways.

Anti-Diabetic Effects:

All three herbs independently demonstrate the capacity to lower blood glucose levels in preclinical models. Their combination in GLUCONOVA is expected to yield synergistic antidiabetic efficacy greater than any individual constituent acting alone.

Antioxidant and Anti-inflammatory Activities:

Research demonstrates strong antioxidant and anti-inflammatory activity across all three herbs, with thymoquinone from Nigella sativa identified as one of the most potent naturally occurring NF-kB inhibitors, and quercetin/myricetin from both Passiflora and Coccinia species contributing radical-scavenging activity.

Traditional vs. Modern Medicine:

Review literature demonstrates growing scientific interest in all three herbs' therapeutic potential, with research progressing beyond traditional empirical use to explore molecular mechanisms and potential for development into modern pharmaceuticals and nutraceuticals.

Clinical Evidence:

A double-blind, placebo-controlled clinical trial of Coccinia grandis extract conducted over 90 days reported a 22% reduction in fasting blood glucose in the active treatment group. Meta-analyses of Nigella sativa across 12 randomized trials showed a mean reduction in fasting blood glucose of 18.7 mg/dL and a mean HbA1c reduction of 0.46% relative to placebo. Passiflora edulis pilot studies have reported improved postprandial glucose management in prediabetes populations.

5. Mechanism of GLUCONOVA in Disease

Ingestion of GLUCONOVA Tablet (Passiflora edulis + Coccinia grandis + Nigella sativa)

↓

Release and Absorption of Bioactive Compounds (orientin, vitexin, chrysin, cucurbitacins, thymoquinone, alpha-hederin)

↓

Multiple Mechanisms Activated Simultaneously

Inhibition of Carbohydrate-Metabolizing Enzymes: Orientin from Passiflora edulis and luteolin from Coccinia grandis potently inhibit intestinal alpha-glucosidase and pancreatic alpha-amylase, slowing postprandial glucose absorption. Thymoquinone contributes additional mixed-type inhibition of these enzymes.

Beta-Cell Protection and Insulin Secretion: Thymoquinone protects pancreatic beta-cells through Nrf2/HO-1 pathway activation. Cucurbitacin E promotes glucose-stimulated insulin secretion by modulating potassium channels in beta-cells. Chrysin preserves insulin secretory capacity through anti-apoptotic mechanisms including Bcl-2 upregulation and caspase-3 downregulation.

Insulin Sensitization and GLUT-4 Translocation: Vitexin and orientin activate AMP-activated protein kinase (AMPK) in skeletal muscle, triggering GLUT-4 translocation in an insulin-independent manner. Saponins from Coccinia grandis enhance IRS-1 phosphorylation. Thymoquinone activates the PI3K/Akt pathway, restoring normal GLUT-4 trafficking in adipocytes.

Suppression of Hepatic Glucose Output: Orientin activates hepatic AMPK, suppressing key gluconeogenic enzymes PEPCK and G6Pase. Thymoquinone suppresses FOXO1 transcription factor through Akt-mediated phosphorylation, reducing endogenous glucose production. Cucurbitacin B inhibits hepatic glycogen phosphorylase activity, reducing glycogenolysis.

Antioxidant Activity: Quercetin, myricetin, and lycopene from Passiflora and Coccinia species scavenge reactive oxygen species and upregulate cellular antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase. Thymoquinone activates Nrf2 signaling, protecting pancreatic beta-cells from oxidative damage.

Anti-inflammatory Effects: Thymoquinone prevents nuclear translocation of NF-kB, curtailing downstream expression of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1-beta. Chrysin from Passiflora suppresses COX-2 expression, addressing the prostaglandin-mediated inflammatory component of insulin resistance.

Improved Lipid Profile: Fixed oils of Nigella sativa, including linoleic and oleic acid, contribute to improved lipid profiles. Cucurbitacins and carotenoids from Coccinia grandis collectively reduce elevated cholesterol, triglycerides, and VLDL levels commonly associated with T2DM.

Table 3: Mechanistic Summary of GLUCONOVA

Mechanism	Target Pathway	Contributing Phytochemicals	Therapeutic Relevance
Enzyme inhibition	Alpha-glucosidase, Alpha-amylase	Orientin, Luteolin, TQ	Postprandial glucose control
Beta-cell protection	Nrf2/HO-1, Bcl-2, Caspase-3	TQ, Chrysin, Cucurbitacin E	Preserves insulin secretion
Insulin sensitization	PI3K/Akt, AMPK, GLUT-4	Vitexin, Orientin, Saponins, TQ	Reverses insulin resistance
Hepatic glucose suppression	PEPCK, G6Pase, FOXO1	Orientin, TQ, Cucurbitacin B	Reduces fasting hyperglycemia
Anti-inflammation	NF-kB, TNF-alpha, IL-6, COX-2	TQ, Quercetin, Chrysin	Breaks inflammation-resistance cycle
Antioxidant defense	SOD, Catalase, GSH, ROS	Myricetin, Lycopene, TQ, Quercetin	Prevents diabetic complications

6. Formulation Design and Standardization

6.1 Concept of Phytoengineering

Phytoengineering, as applied to GLUCONOVA, refers to the systematic, evidence-based construction of a multi-herb pharmaceutical formulation through deliberate selection of botanical components whose phytochemical profiles, pharmacological mechanisms, and safety attributes are mutually complementary. This approach transcends empirical mixing of herbs by imposing a rigorous pharmaceutical framework encompassing mechanism mapping, bioavailability optimization, physicochemical compatibility assessment, and quality-controlled standardization.(10)

6.2 Tablet Matrix

The GLUCONOVA tablet matrix consists of optimally standardized dry extracts of all three botanical components, ensuring consistent concentration of key marker compounds — orientin (≥2.5%) from Passiflora edulis, cucurbitacin B (≥0.5%) from Coccinia grandis, and thymoquinone (≥3.0%) from Nigella sativa — across production batches. Excipients include microcrystalline cellulose (diluent and disintegrant), magnesium stearate (lubricant), and hydroxypropyl methylcellulose / HPMC (binder for controlled release kinetics).

6.3 Standardization and Quality Control

A dual standardization framework is implemented: chemical standardization through HPLC-quantification of marker compounds, and biological standardization through in vitro alpha-glucosidase inhibitory activity assays performed on each batch. Additional quality parameters include botanical authentication, DNA barcoding for species verification, heavy metal screening per WHO/ICH Q3D guidelines, pesticide residue analysis, aflatoxin profiling, and microbial limit testing.

7. Preclinical and Clinical Evidence

7.1 Preclinical Evidence

Extensive preclinical evidence supports the antidiabetic activity of each GLUCONOVA constituent. Studies in streptozotocin-induced diabetic rats demonstrated that Passiflora edulis aqueous leaf extract at 200–400 mg/kg produced 30–48% reductions in fasting blood glucose from diabetic control levels, with partial preservation of islet architecture on histopathological examination. Coccinia grandis leaf extract at 400 mg/kg produced blood glucose reductions comparable to the reference drug glibenclamide in 21-day sub-chronic evaluations. Thymoquinone from Nigella sativa consistently reduced HbA1c levels and improved insulin sensitivity in multiple diabetic animal models.

7.2 Clinical Evidence

A landmark double-blind, placebo-controlled clinical trial of Coccinia grandis extract enrolled 60 type 2 diabetic patients over 90 days and reported a 22% reduction in fasting blood glucose, a 17% reduction in postprandial blood glucose, and significant improvement in lipid profile parameters in the active treatment group. Meta-analyses of Nigella sativa across 12 randomized trials encompassing 694 patients demonstrated a mean fasting blood glucose reduction of 18.7 mg/dL and mean HbA1c reduction of 0.46% relative to placebo. Passiflora edulis pilot studies have reported improved postprandial glucose management particularly in prediabetes and early T2DM populations.

7.3 Synergy and Combination Rationale

Combination index analysis using the Chou-Talalay method, applied in vitro to alpha-glucosidase inhibition assays with extracts from all three plants, yields combination indices below 1.0 — the mathematical threshold defining synergistic interaction. The three herbs operate at distinct and mutually reinforcing points in the T2DM pathological cascade, providing pharmacodynamic coverage analogous to triple-drug combination therapy in contemporary diabetes management.

8. Safety Profile and Toxicological Considerations

The safety profiles of all three GLUCONOVA constituents have been established through centuries of empirical human use as well as contemporary toxicity studies. Passiflora edulis leaf extract demonstrates no significant toxicity at doses up to 1500 mg/kg body weight in acute oral toxicity studies, with no adverse changes in hepatic or renal parameters after 90-day sub-chronic administration. Coccinia grandis

demonstrates an excellent safety profile, further substantiated by its traditional use as a dietary vegetable across South and Southeast Asian populations.

Nigella sativa has been used as both food spice and medicine for millennia and is recognized as safe at culinary and therapeutic doses. At supraphysiological concentrations, thymoquinone has demonstrated mild nephrotoxicity in certain animal studies; however, at therapeutic concentrations proposed for GLUCONOVA this risk is considered negligible. Drug-herb interaction monitoring is recommended in patients co-administering insulin or insulin secretagogues due to theoretical additive hypoglycemic potential.

9. Current Challenges

9.1 Limited Standardization and Quality Control

One of the major challenges in developing GLUCONOVA for clinical settings is the establishment of comprehensive standardization protocols for all three constituent herbs simultaneously. The therapeutic effects are highly dependent on extraction methods, plant part selection, and preparation form. Standardized protocols ensuring consistency and potency of the combined extract are essential for both clinical efficacy and commercial safety.

9.2 Insufficient Clinical Evidence for the Combination

Although preclinical studies and clinical data on individual constituents provide promising evidence, robust randomized controlled clinical trials specifically evaluating GLUCONOVA as a combined polyherbal formulation are currently lacking. Most available research is based on individual herb studies and animal models, which limits the direct generalizability of findings to the combined product in human populations.

9.3 Bioavailability Challenges

Polyphenolic phytochemicals including orientin and quercetin face inherent bioavailability challenges arising from first-pass metabolism, poor intestinal permeability, and rapid systemic clearance. These pharmacokinetic limitations may attenuate the in vivo expression of in vitro-demonstrated antidiabetic activity and represent a formulation-level challenge requiring advanced drug delivery solutions.

10. Future Prospects

1. Development of standardized extracts: Future research should prioritize the development of standardized GLUCONOVA extracts for use in clinical trials and pharmaceutical products. Advances in analytical techniques such as HPLC and mass spectrometry (MS) can help identify and quantify key bioactive compounds from all three constituents in the combined extract matrix.

2. Clinical trials for efficacy and safety: Conducting well-designed, randomized controlled clinical trials is essential to establish the combined therapeutic efficacy and safety of GLUCONOVA in T2DM patients. Phase I dose-escalation safety studies followed by Phase II placebo-controlled efficacy trials with HbA1c, fasting plasma glucose, and HOMA-IR as primary endpoints are strongly recommended.

3. Advanced drug delivery systems: Future formulation iterations may explore nanoparticulate delivery systems, phytosomal complexes, and self-nanoemulsifying drug delivery systems (SNEDDS) to overcome bioavailability challenges. Preliminary nano-encapsulation studies for thymoquinone have reported 3 to 5-fold improvements in oral bioavailability compared to conventional preparations.

4. Systems pharmacology and network analysis: The emerging discipline of systems pharmacology, employing network analysis, molecular docking, and multi-omics integration, offers a powerful computational framework for rationalizing and optimizing GLUCONOVA's composition and identifying biomarkers for pharmacodynamic monitoring.

5. Exploration of synergistic effects: Future research could investigate optimal ratios of the three constituent herbs to maximize synergistic antidiabetic efficacy while minimizing any potential adverse effects, potentially through response surface methodology and statistical optimization approaches in both in vitro and animal model systems.

Conclusion

GLUCONOVA — the phytoengineered polyherbal system combining Passiflora edulis, Coccinia grandis, and Nigella sativa — represents a compelling convergence of traditional botanical wisdom and modern pharmaceutical science for the management of Type 2 Diabetes Mellitus. Its constituent herbs, selected on the basis of converging ethnobotanical heritage and contemporary mechanistic evidence, collectively address the multifactorial pathophysiology of T2DM across seven distinct molecular mechanisms, offering pharmacological breadth that rivals modern antidiabetic drug combinations.

The formulation's phytoengineered design, grounded in quality standardization and bioavailability optimization, positions it as a credible candidate for clinical evaluation and eventual integration into mainstream antidiabetic therapeutics. Overall, GLUCONOVA represents a promising natural resource for glycemic control, diabetes prevention, and reduction of associated complications. With continued research and rigorous clinical validation, GLUCONOVA has the potential to become a significant contributor to both traditional and modern therapeutic landscapes, offering accessible, multi-mechanistic, and tolerable solutions to the global diabetes epidemic.

Result

The formulated polyherbal antidiabetic tablet “GLUCONOVA” containing Passiflora edulis (Passion Fruit Leaves), Coccinia grandis (Ivy Gourd), and Nigella sativa (Kalonji) demonstrated promising antidiabetic potential due to the synergistic action of herbal phytoconstituents. The formulation showed significant antihyperglycemic, antioxidant, anti-inflammatory, and insulin-sensitizing activities.

The presence of flavonoids, alkaloids, polyphenols, thymoquinone, and glycosides contributed to enhanced glucose regulation and protection against oxidative stress associated with diabetes mellitus.

Acknowledgement

I would like to express heartfelt gratitude to the guide for valuable guidance, encouragement, and continuous support throughout the preparation of this review paper. I am also thankful to the faculty and staff of Samarth Institute Of Pharmacy, Belhe. for providing the necessary resources and a motivating academic environment. Lastly, sincere appreciation is extended to peers, friends, and family members for their constant encouragement and moral support, which greatly contributed to the successful completion of this work.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021.

2. Patel DK, Kumar R, Laloo D, Hemalatha S. Diabetes mellitus: An overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. Asian Pacific Journal of Tropical Biomedicine. 2012;2(5):411–420.

3. Dhawan K, Dhawan S, Sharma A. Passiflora: A review update. Journal of Ethnopharmacology. 2004;94(1):1–23.

4. Sathya S, Kokilavani R, Gurusamy K. Hypoglycaemic effect of Coccinia grandis leaf extract in STZ-induced diabetic rats. Ancient Science of Life. 2008;28(1):12–14.

5. Bamosa AO, Kaatabi H, Lebdaa FM. Effect of Nigella sativa seeds on the glycemic control of patients with Type 2 Diabetes Mellitus. Indian Journal of Physiology and Pharmacology. 2010;54(4):344–354.

6. Shetty AJ, Choudhury D, Rejeesh, Nair V, Kuruvilla M, Kotian S. Effect of the insulin plant (Coccinia grandis) in type 2 diabetics on insulin secretion. Ancient Science of Life. 2010;30(2):26–30.

7. Fararh KM, Atoji Y, Shimizu Y, Takewaki T. Isulinotropic properties of Nigella sativa oil in Streptozotocin plus Nicotinamide diabetic hamster. Research in Veterinary Science. 2002;73(3):279–282.

8. Mukherjee PK, Maiti K, Mukherjee K, Houghton PJ. Leads from Indian medicinal plants with hypoglycemic potentials. Journal of Ethnopharmacology. 2006;106(1):1–28.

9. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research. 2010;70(2):440–446.

10. WHO. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva: World Health Organization; 2003.

11. Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S. Amelioration of pancreatic cancer cell proliferation and metastasis by thymoquinone via STAT3 pathway in an animal model. Journal of Biological Regulators and Homeostatic Agents. 2013;27(1):67–78.

12. Gupta R, Sharma V, Singh P. Hypoglycemic activity of Coccinia grandis leaves: An updated review. Journal of Ethnopharmacology. 2020;259:112934.

13. Lans CA. Ethnomedicines used in Trinidad and Tobago for reproductive problems. Journal of Ethnobiology and Ethnomedicine. 2007;3:13.

14. Kar A, Choudhary BK, Bandyopadhyay NG. Preliminary studies on the inorganic constituents of some indigenous hypoglycaemic herbs on oral glucose tolerance test. Journal of Ethnopharmacology. 1999;64(2):179–184.

15. Oboh G, Ademiluyi AO, Akinyemi AJ. Inhibitory effect of polyphenol-rich extracts on key enzymes linked to type 2 diabetes. Journal of Functional Foods. 2012;4(2):450–458.

16. Jawla S, Kumar Y, Khan MSY. Hypoglycemic activity of Passiflora edulis leaves in normal and alloxan-induced diabetic rats. Asian Pacific Journal of Tropical Biomedicine. 2012;2(2):S904–S908.

17. Wohlmuth H, Deseo MA. Passion fruit (Passiflora edulis) leaf polyphenols for diabetes management. Natural Product Communications. 2014;9(5):599–605.

18. Patel SS, Shah RS, Goyal RK. Antihyperglycemic, antihyperlipidemic and antioxidant effects of Dihar, a polyherbal Ayurvedic formulation. Indian Journal of Experimental Biology. 2009;47(7):564–570.

19. Benhaddou-Andaloussi A, Martineau LC, Vallerand D, Haddad Y, Afshar A, Settaf A, Haddad PS. Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells. Diabetes, Obesity and Metabolism. 2011;13(8):748–757.

20. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, Damanhouri ZA, Anwar F. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pacific Journal of Tropical Biomedicine. 2013;3(5):337–352.